Latest Conference Articles

Lenalidomide as maintenance following first-line immunochemotherapy substantially improves progression-free survival in the treatment of patients with high-risk chronic lymphocytic leukemia.

The combination of the killer-cell immunoglobulin-like receptors inhibitor lirilumab with the hypomethylating agent azacytidine was well tolerated and showed early signals of activity in heavily pretreated patients with acute myeloid leukemia.

Treatment with enasidenib was active and was well tolerated in pretreated patients with IDH2-mutated myelodysplastic syndrome, including those who failed hypomethylating agents.

Researchers are hopeful that the addition of the investigational agent vadastuximab talirine to standard 7+3 induction therapy may improve survival for patients with acute myeloid leukemia.

The CAR T-cell therapy CTL019 demonstrated an 82% complete remission (CR) or CR with incomplete blood count recovery rate for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Mrinal S. Patnaik, MBBS, hematologist, Mayo Clinic, discusses a study investigating SL-401 in patients with myeloproliferative neoplasms during the American Society of Hematology (ASH) Annual Meeting.

Constantine Tam, MD, discusses 2 trials investigating BTK inhibitor BGB-3111 in chronic lymphocytic leukemia (CLL) and Waldenstrom’s macroglobulinemia.

TKIs can safely be stopped or dose-reduced without jeopardizing long-term outcomes for select patients with chronic myeloid leukemia who have obtained a major molecular response.

Brentuximab vedotin induced responses lasting at least 4 months in 56% of patients with cutaneous T-cell lymphoma versus 13% in patients receiving physician’s choice of standard therapies, according to findings from the phase III ALCANZA trial presented at the 2016 ASH Annual Meeting.

CPX-351 may provide a bridge to successful transplantation for older patients with acute myeloid leukemia with limited treatment options.

Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia, many of whom had prior anti-CD19 CAR T-cell therapy.

The next-generation BTK inhibitor acalabrutinib produced an objective response rate of 38.1% as a monotherapy for patents with Richter transformation.

Treatment with the combination of nivolumab and ibrutinib showed encouraging activity and safety in a small phase II study of patients with chronic lymphocytic leukemia and Richter transformation.

Manmeet Ahluwalia, MD, FACP, Miller Family Endowed Chair in Neuro-Oncology and Head of Operations, Burkhardt Brain Tumor NeuroOncology Center, discuses a new classification system for brain metastases.

Antonio Iavarone, MD, professor of Pathology and Cell Biology and Neurology, Columbia University, Institute for Cancer Genetics, discusses the role of the ID2 protein in patients with malignant brain tumors.

Researchers are hoping that a proposed phase II study exploring use of the Optune system in patients with recurrent grade III malignant glioma will expand the indications for the tumor treating fields (TTFields) device beyond its current FDA-approved use in recurrent grade IV glioblastoma.

Treatment with nivolumab and radiotherapy with or without concurrent temozolomide was well tolerated and showed promising signs of efficacy for patients with newly-diagnosed glioblastoma multiforme.

The PD-L1 inhibitor durvalumab generated durable responses in bevacizumab-naïve patients with recurrent glioblastoma multiforme.

Treatment with AG-120 at an established dose of 500 mg induced a stable disease rate of 83% and a minor response rate of 9% for patients with non-enhancing IDH1-mutated glioma.

Daniel O'Connell, MD, University of California at Los Angeles, discusses a phase II trial testing the benefits of tumor treating fields with Optune for bevacizumab-naive patients with grade III malignant glioma.

Updated data from the phase III EF-14 study showed that adding Optune to temozolomide improved overall survival by 4.8 months compared with temozolomide alone in patients with newly diagnosed glioblastoma multiforme.

Pembrolizumab had a 6-month progression-free survival rate of 44% and a manageable safety profile for patients with recurrent PD-L1-positive glioblastoma multiforme.

Findings from the phase II trials KEYNOTE-028 of pembrolizumab and MEDI4736 (durvalumab) point to a role for checkpoint inhibitors in the treatment of glioblastoma multiforme, based on encouraging efficacy signals and safety data with the two agents.

Combination therapy with ibudilast and temozolomide for glioblastoma multiforme increased apoptosis and prolonged survival by significantly reducing macrophage inhibitory factor and receptor CD74 expression.

A phase I trial of the antibody drug conjugate ABT-414 has shown promising results for the treatment of patients with EGFR-amplified, recurrent glioblastoma.

Martin J. van den Bent, MD, ‎Head Neuro-Oncology Unit at Erasmus MC Cancer Center, discusses what the next trials will be for ABT-414, anti-EGFR antibody-drug conjugate under exploration for patients with brain cancer.

Arie Perry, MD, chief of Neuropathology, University of California, San Francisco, discusses the potential implications of the new World Health Organization central nervous system tumor classifications.